期刊
TRANSPLANTATION PROCEEDINGS
卷 41, 期 2, 页码 463-465出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.transproceed.2009.01.027
关键词
-
资金
- NHLBI NIH HHS [5R01 HL063442, R01 HL063442-01A2, R01 HL063442] Funding Source: Medline
- NIDDK NIH HHS [R01 DK069766-01A1, R01 DK069766] Funding Source: Medline
Composite tissue allotransplantation (CTA) transplantation is currently being performed with increasing frequency in the clinic. The feasibility of the procedure has been confirmed in over 40 successful hand transplants, 3 facial reconstructions, and vascularized knee, esophageal, abdominal wall, and tracheal allografts. The toxicity of chronic, nonspecific immunosuppression remains a major limitation to the widespread availability of CTA and is associated with opportunistic infections, nephrotoxicity, end-organ damage, and an increased rate of malignancy. Methods to reduce or eliminate the requirement for immunosuppression would represent a significant step forward in the field. Mixed chimerism induces tolerance to solid organ and tissue allografts, including CTA. This overview focuses on the history and expanding applications of CTA as a new frontier in transplantation, and considers the important hurdles that must be overcome through research to allow widespread clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据